Irinotecan, Oxaliplatin Plus Bolus 5-Fluorouracil and Low Dose Folinic Acid Every 2 Weeks

• DOI: 10.1097/01.coc.0000196200.49373.d5
• Publication Date: 2006-02-06T09:02:49Z
• Authors: Justina Martinez; Claudio Martin; Matias Chacon; Ernesto Korbenfeld; Santiago Bella; Susana Senna; Eduardo Richardet; Federico Coppola; Carlos Bas; Jorge Hidalgo; Emiliano Escobar; Monica Reale; Andres M. Smilovich; Ernesto Wasserman
• Keywords: Folinic acid; Bolus (digestion)

Objectives: Irinotecan or oxaliplatin combined with 5-fluorouracil (5-FU) ± folinic acid (FA) has changed the treatment standards for metastatic colorectal cancer (CRC). The and irinotecan combination reported consistent activity. purpose of this phase II study was to assess efficacy safety simultaneous administration a triple chemotherapy oxaliplatin, irinotecan, 5-FU bolus, FA. Materials Methods: Eligible patients had CRC no prior irinotecan-based chemotherapy. Treatment consisted 85 mg/m2 followed by 150 mg/m2, repeated every 15 days, 500 bolus FA 20 on days 1, 8, 15. An early amendment suppressed day 8 5-FU/FA. Results: Twenty-six eligible treated receiving 253 doses were assessed toxicity. Myelosuppression most frequent toxicity; grade 3 4 neutropenia febrile occurred in 50% 15% patients, respectively. schedule modification, omitting dosing considerably improved compliance, reducing incidence neutropenia, diarrhea, asthenia. Among 25 evaluable efficacy, 10 objective responses including 1 complete response (CR) (4%) 9 partial (PR) (36%), giving an overall rate 40%. Median time progression 6.20 months [95% confidence interval (CI), 5.44–6.96]. survival 12.95 months. Conclusions: produced promising acceptable toxicity but does not seem produce evident benefit time-related parameters.